Sanofi $SNY Holdings Decreased by Cullen Capital Management LLC

Cullen Capital Management LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 12.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 384,482 shares of the company’s stock after selling 53,342 shares during the period. Cullen Capital Management LLC’s holdings in Sanofi were worth $18,148,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the business. Financial Consulate Inc. purchased a new position in Sanofi during the 3rd quarter valued at about $26,000. Ameritas Advisory Services LLC purchased a new position in Sanofi during the second quarter valued at approximately $28,000. First Horizon Corp acquired a new position in Sanofi in the 3rd quarter valued at approximately $33,000. Salomon & Ludwin LLC lifted its position in Sanofi by 1,046.3% in the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock worth $39,000 after buying an additional 701 shares in the last quarter. Finally, Concord Wealth Partners boosted its stake in shares of Sanofi by 510.3% during the 2nd quarter. Concord Wealth Partners now owns 885 shares of the company’s stock valued at $43,000 after buying an additional 740 shares during the period. 14.03% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Price Performance

NASDAQ SNY opened at $48.08 on Thursday. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The company has a fifty day simple moving average of $48.00 and a 200 day simple moving average of $48.67. The company has a current ratio of 1.09, a quick ratio of 0.29 and a debt-to-equity ratio of 0.20. The company has a market cap of $117.27 billion, a P/E ratio of 13.36, a P/E/G ratio of 1.23 and a beta of 0.45.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SNY. Barclays downgraded shares of Sanofi from an “overweight” rating to an “equal weight” rating in a research note on Tuesday, January 6th. HSBC restated a “buy” rating on shares of Sanofi in a research note on Wednesday, December 10th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, December 8th. UBS Group restated a “neutral” rating on shares of Sanofi in a report on Friday, January 16th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Sanofi in a research note on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $62.67.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.